For the past two years, GB Sciences has been working towards the creation of novel, patentable cannabis-based formulations under the leadership of Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences, Inc. “This patent application is the first in a series that were invented based on our novel approach to creating cannabis-based therapies.”
Our production facility in Nevada is the seat of innovative tissue-culture propagation. It’s where we grow clean, consistent strains of cannabis for use in biopharmaceutical research and product development.
We are committed to our mission of serving patients. We are a small, smart company, which means we are nimble and flexible enough to respond to new discoveries. And as a result we stand at the forefront of innovation and discovery in cannabis cultivation, propagation, and research.
The research and development team at GB Sciences is actively pursuing new formulations derived from specific strains of cannabis, creating patented formulations that will help patients.
At GB Sciences, we have two equally important constituencies–the patients who need what we do, and the investors that support what we do. Without the latter, we could not help the former.
Our growth strategy is two pronged–while we continue to explore the leading edge of biomedical research for the development of cannabis-based therapies, we also take advantage of the recreational market for cannabis in Nevada.